- Home
- BMRN vs QGEN Comparison
BMRN vs QGEN Comparison
Compare BMRN & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- QGEN
- Stock Information
- Founded
- BMRN 1996
- QGEN 1986
- Country
- BMRN United States
- QGEN Netherlands
- Employees
- BMRN N/A
- QGEN N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BMRN Health Care
- QGEN Health Care
- Exchange
- BMRN Nasdaq
- QGEN Nasdaq
- Market Cap
- BMRN 10.0B
- QGEN 10.7B
- IPO Year
- BMRN 1999
- QGEN 1996
- Fundamental
- Price
- BMRN $52.08
- QGEN $44.11
- Analyst Decision
- BMRN Buy
- QGEN Buy
- Analyst Count
- BMRN 19
- QGEN 7
- Target Price
- BMRN $90.89
- QGEN $50.68
- AVG Volume (30 Days)
- BMRN 2.8M
- QGEN 1.0M
- Earning Date
- BMRN 10-27-2025
- QGEN 11-04-2025
- Dividend Yield
- BMRN N/A
- QGEN 3.42%
- EPS Growth
- BMRN 59.53
- QGEN 405.09
- EPS
- BMRN 2.68
- QGEN 1.69
- Revenue
- BMRN $3,094,001,000.00
- QGEN $2,040,067,000.00
- Revenue This Year
- BMRN $13.32
- QGEN $7.37
- Revenue Next Year
- BMRN $7.51
- QGEN $5.65
- P/E Ratio
- BMRN $19.59
- QGEN $26.98
- Revenue Growth
- BMRN 12.39
- QGEN 5.15
- 52 Week Low
- BMRN $51.00
- QGEN $37.63
- 52 Week High
- BMRN $73.51
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- BMRN 42.64
- QGEN 31.22
- Support Level
- BMRN $51.80
- QGEN $43.26
- Resistance Level
- BMRN $54.25
- QGEN $47.39
- Average True Range (ATR)
- BMRN 1.73
- QGEN 1.05
- MACD
- BMRN -0.03
- QGEN -0.53
- Stochastic Oscillator
- BMRN 18.34
- QGEN 13.43
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).